SNSS, running hugely. So SNSSW is going to follow. SNSS was as High as $3.6.
That was a painful shakeout this morning, but well needed. Too many long positions needed to be closed out. Adam F, your timing is questionable but admirable this time. Whats your motive?
Just by chance I watched a continuing medical education session by Dr. David Steensma, to whom Feurstein attributed very negative comments. This is NOT the case in the CME program, which I invite you to watch. Steensma acknowledges that Valor was a big study and came pretty close to statistical significance, and if you sensor out the patients who had bone marrow transplant, it did achieve significance! He regards the study as a baby step forward, Steemsa says nothing about the drug not being a candidate for approval
Saturday's Best of the Day from the 2014 Annual Hematology Meeting in San Francisco
Imedex is pleased to present Best of the DaySM from the 2014 Annual Hematology Meeting. This daily update is brought to you direct from the meeting in San Francisco, California, USA..
In today’s online streaming video program, I am joined by Drs. Srdan Verstovsek and David P. Steensma to explore the most clinically relevant, new, and updated data presented in today's sessions. The topics will include Myeloproliferative Neoplasms, Myelodysplastic Syndromes, Acute Lymphocytic Leukemia, and Acute Myeloid Leukemia.
If you have a mobile device:
Srdan Verstovsek, MD, PhD
View mobile version
Myelodysplastic Syndromes, ALL, and AML
David P. Steensma, MD
View mobile version
Think for yourself chump. Trial is significant at 0.06 p-value. Not significant at 0.05 p-value. This is not a Yes/No situation. This is saying that there is not 5% chance the trial was due to randomness. This is saying that there is 6% chance this is due to randomness. That does not mean trial failed. You must think for yourself chump. Thank you.
From the street
Listening to Ravandi's encomium to vosaroxin was surreal because the phase III study failed. Elderly AML patients treated with vosaroxin and cytarabine did not live any longer than patients treated with cytarabine alone. The 13% reduction in the risk of death favoring vosaroxin was NOT statistically significant. There's a sliver of daylight between the overall survival curves, but even this tiny sign of hope is a false signal. Remember,Sunesis added 225 patients to the study at an interim analysis to improve the odds of success.
"Despite 40 years of intense clinical research, there remain no new approved treatments or standard of care for patients with relapsed or refractory AML," said Farhad Ravandi, M.D., Professor of Medicine, Department of Leukemia, University of Texas MD Anderson Cancer Center, and a principal investigator of the VALOR study. "Vosaroxin and cytarabine demonstrated increased overall survival and higher complete response rates in this setting without increased early mortality, a result particularly pronounced in the poorest prognosis treatment settings, including patients over 60 years old. These data support the use of this combination as a new treatment option for patients with relapsed or refractory AML."
"When we compare AML to other blood cancers, the complete absence of new therapies introduced in the last two decades, particularly in the United States, speaks to a massive void for so many patients," said Patricia J. Goldsmith, CEO of CancerCare(R). "These patients should not wait any longer for a breakthrough; they deserve new treatment options today."